Cancer, Obesity and Visceral Fat: Key Facts

Cancer, obesity and visceral fat are closely linked, with excess abdominal fat now recognised as the second largest preventable cause of cancer in the UK after smoking. Visceral fat, which accumulates deep within the abdominal cavity around vital organs, is metabolically active and drives chronic inflammation, hormonal disruption and altered cell signalling in ways that may promote tumour development. Understanding how visceral fat increases cancer risk, which cancers are most affected, and what practical steps can reduce that risk is important for anyone looking to protect their long-term health.

How does visceral fat increase your risk of cancer?

Visceral fat increases cancer risk through chronic low-grade inflammation, elevated oestrogen, insulin and IGF-1, and reduced adiponectin, all of which may promote abnormal cell growth and impair the body's defences against tumours.

Visceral fat is associated with increased cancer risk primarily through chronic low-grade inflammation and disruption of the hormonal environment in ways that may promote abnormal cell growth. Unlike subcutaneous fat, which sits just beneath the skin, visceral fat accumulates deep within the abdominal cavity, surrounding organs such as the liver, pancreas and intestines. This location makes it metabolically active in ways that observational and translational research suggests are particularly harmful over time.

One key mechanism involves the release of pro-inflammatory signalling molecules called cytokines, including interleukin-6 and tumour necrosis factor-alpha. These compounds are associated with a sustained inflammatory state that may damage DNA and impair the body's normal mechanisms for detecting and destroying abnormal cells. Chronic inflammation is recognised in the research literature as a significant factor in cancer development across multiple organ systems, though much of the supporting evidence is observational.

Visceral fat is also associated with altered hormone levels that may favour tumour growth. Excess adipose tissue is linked with higher circulating oestrogen (through a process called aromatisation), raised insulin and insulin-like growth factor-1 (IGF-1) levels, and lower adiponectin.^[23][24] Lower adiponectin levels have been associated with higher cancer risk in observational studies, though the direction of causality is not fully established.^[12][13] Elevated insulin and IGF-1 act as growth signals that may accelerate the proliferation of pre-cancerous and cancerous cells.^[18][19]

Additionally, visceral fat is associated with higher levels of leptin, a hormone that, at chronically elevated concentrations, may stimulate cell division and inhibit apoptosis (programmed cell death).^[21][22] Together, these biological pathways help explain why carrying excess weight, particularly around the abdomen, is independently associated with an increased risk of developing several types of cancer, even in people who might otherwise appear healthy by other measures.

A practical way to assess central adiposity is to measure waist circumference or calculate waist-to-height ratio. NICE guidance notes that waist circumference and waist-to-height ratio can identify people at increased metabolic risk, and that risk thresholds differ by ethnic group. Speak to your GP if you are unsure how to interpret your measurements.

Which cancers are most strongly linked to obesity in the UK?

Cancer Research UK links at least 13 cancer types to excess body weight, with bowel, post-menopausal breast, endometrial and oesophageal adenocarcinoma among the most strongly associated, making obesity the second largest preventable cause of cancer in the UK.

Cancer Research UK identifies at least 13 cancer types as having a strong evidence-based link to excess body weight, making obesity the second largest preventable cause of cancer in the UK after smoking. The association is not uniform across all cancer types; some show a particularly robust relationship with visceral adiposity and the hormonal and inflammatory changes it produces.

The cancers most consistently linked to obesity in the UK include:

• Bowel (colorectal) cancer: One of the most common obesity-related cancers in the UK, with risk rising progressively with increasing body mass index (BMI).

• Breast cancer (post-menopausal): Elevated oestrogen from adipose tissue is a key driver; the link is strongest in women who have been through the menopause.

• Endometrial (womb) cancer: Excess oestrogen from visceral fat is a major risk factor, and obesity is estimated to account for a substantial proportion of cases.

• Oesophageal adenocarcinoma: Strongly associated with obesity, partly through the link with gastro-oesophageal reflux disease.^[26][27]

• Stomach (cardia) cancer, kidney (renal cell) cancer, pancreatic cancer, liver cancer, gallbladder cancer, ovarian cancer, thyroid cancer, meningioma and multiple myeloma also feature on the list of obesity-associated malignancies identified by Cancer Research UK and the World Cancer Research Fund.

It is important to note that having obesity does not mean a person will develop cancer, and many people with a healthy weight do develop these conditions. However, the population-level data are clear: reducing excess body fat, particularly visceral fat, is one of the most meaningful lifestyle steps a person can take to lower their overall cancer risk. The Office for Health Improvement and Disparities (OHID) and Cancer Research UK both highlight weight management as a priority in cancer prevention strategies.

How can you reduce visceral fat and lower your cancer risk?

Reducing visceral fat requires sustained dietary change, at least 150 minutes of moderate aerobic activity per week, and limiting alcohol, with clinically supervised weight management available for those with a BMI of 30 or above.

Reducing visceral fat requires a sustained combination of dietary change, increased physical activity and, where appropriate, clinical support. Research suggests that visceral fat may respond well to lifestyle intervention even when overall weight loss is modest, and some studies indicate it is among the first fat depots to decrease with meaningful lifestyle changes, though individual responses vary.

Dietary approaches that are supported by evidence include:

• Reducing ultra-processed foods, refined carbohydrates and added sugars, which are associated with higher insulin levels and abdominal fat accumulation in observational studies.

• Increasing dietary fibre from vegetables, legumes and wholegrains, which supports gut health and is associated with reduced inflammatory markers.

• Following a Mediterranean-style eating pattern, which has been associated with lower visceral fat and reduced cancer risk in observational studies; most of the supporting evidence is from cohort data rather than randomised trials.

Physical activity is particularly effective at reducing visceral fat, even without significant changes on the scales. The UK Chief Medical Officers' Physical Activity Guidelines recommend at least 150 minutes of moderate-intensity aerobic activity per week for adults, or 75 minutes of vigorous-intensity activity, alongside muscle-strengthening activities on two or more days.^[5][6] Both aerobic exercise and resistance training contribute to visceral fat reduction.

Avoiding or limiting alcohol is also relevant. Alcohol contributes to abdominal fat accumulation and is itself an independent risk factor for several cancers, including breast, bowel and liver cancer.^[28][29] The UK Chief Medical Officers advise that the lowest risk to health from alcohol is achieved by not drinking, and that if people do drink, keeping to no more than 14 units per week reduces the risk.^[8] NHS and Cancer Research UK resources provide further detail on alcohol and cancer risk.

For people with a BMI of 30 or above (or 27.5 or above in some ethnic groups), clinically supervised weight management may be appropriate. This can include structured behavioural programmes, dietitian support, or, where clinically indicated, pharmacological treatment. Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online weight-management consultations, with prescriber review and pharmacist support, where a range of options may be considered based on individual clinical need.

What does the NHS recommend if you are overweight and concerned about cancer?

The NHS recommends speaking to your GP, who can assess risk, arrange screening and refer to structured weight management services, with MHRA-authorised medicines available where lifestyle measures alone are insufficient.

The NHS recommends that anyone who is overweight and concerned about their cancer risk should speak to their GP in the first instance, as a GP can assess individual risk factors, arrange relevant screening where appropriate, and refer to structured weight management services. Self-referral to NHS weight management programmes is also available in many areas of England through the NHS Digital Weight Management Programme, which offers 12-week behavioural support for adults with a BMI of 30 or above (or 27.5 or above for people from Black, Asian and minority ethnic backgrounds) who also have a diagnosis of hypertension or type 2 diabetes.

NICE guidance (NG246 and related technology appraisals) sets out a stepped approach to weight management, beginning with lifestyle intervention and progressing to pharmacological treatment where lifestyle measures alone have not achieved sufficient benefit.^[1] Medicines authorised by the MHRA for chronic weight management in the UK currently include semaglutide (Wegovy, available as a subcutaneous injection with a maintenance dose of 2.^[11]4 mg weekly and a further authorised strength of 7.2 mg weekly, and also as oral Wegovy 25 mg tablets, MHRA-authorised in June 2026), liraglutide (Saxenda), tirzepatide (Mounjaro, authorised both for type 2 diabetes and for chronic weight management), and orforglipron (Foundayo). Orlistat is also available for weight management. Access to these medicines on the NHS is subject to local Integrated Care Board (ICB) commissioning decisions and specific eligibility criteria. For current product details, including authorised doses and indications, refer to the relevant summaries of product characteristics on the electronic Medicines Compendium (emc).

If you notice any new or unexplained symptoms, such as unexpected weight loss, changes in bowel habits, unusual bleeding or a persistent lump, you should contact your GP promptly rather than waiting. NICE guidance NG12 (Suspected cancer: recognition and referral) sets out the red-flag symptoms that should prompt urgent assessment in primary care.^[3] For urgent concerns that arise outside of GP hours, NHS 111 can provide advice. Cancer screening programmes, including bowel, breast and cervical screening, remain an important part of early detection and are separate from weight management pathways.

Frequently Asked Questions